Sotorasib in KRASG12C mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?

被引:7
作者
Oliver, Timothee [1 ,2 ]
Haslam, Alyson [2 ]
Prasad, Vinay [2 ]
机构
[1] Geneva Univ Hosp, Dept Oncol, 4 Gabrielle Perret Gentil St, CH-1205 Geneva, Switzerland
[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, 550 16th St,2nd Fl, San Francisco, CA 94158 USA
关键词
Non -small cell lung cancer; KRAS inhibitors; Biomarker; Informative censoring; Power analysis; DOCETAXEL;
D O I
10.1016/j.tranon.2022.101591
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The KRAS oncogene is present in up to 25% of solid tumors and for decades had been undruggable. Sotorasib was the first-in-class KRAS inhibitor to reach the US and European market, and its pharmacological inhibition is restricted to the KRAS p.G12C mutation. Sotorasib showed activity (tumor shrinkage) in patients with non-small cell lung cancer harboring this specific mutation, and efficacy was tested in the CodeBreaK 200, open-label, phase 3 trial (NCT04303780). The results were presented in the ESMO 2022 meeting. CodeBreaK 200 found an improvement in the primary endpoint of progression-free survival (PFS), but overall survival, a key secondary endpoint, was not improved. However, critical questions about the trial's design may limit inferences regarding the reported results. The control arm treatment was inferior to the best standard of care. A late protocol modification (which lowered the sample size and allowed a problematic crossover) prohibited the trial from making a determination regarding overall survival. Imbalance in censoring rates, with potential informative censoring, makes PFS estimates unreliable. Quality-of-life data were also limited. Ultimately, CodeBreaK 200 does not clarify how this therapy should be used in practice, and while we maintain cautious enthusiasm for this and other Ras inhibitors, we await more informative trials
引用
收藏
页数:3
相关论文
共 19 条
[1]   STATISTICS NOTES - ABSENCE OF EVIDENCE IS NOT EVIDENCE OF ABSENCE [J].
ALTMAN, DG ;
BLAND, JM .
BRITISH MEDICAL JOURNAL, 1995, 311 (7003) :485-485
[2]  
[Anonymous], History of Changes for Study: NCT01021202
[3]  
[Anonymous], 2022, KRAS G12C IND SOT MA
[4]   Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous nonesmall-cell lung cancer: Results of the IFCT-1103 ULTIMATE study [J].
Cortot, Alexis B. ;
Audigier-Valette, Clarisse ;
Molinier, Olivier ;
Le Moulec, Sylvestre ;
Barlesi, Fabrice ;
Zalcman, Gerard ;
Dumont, Patrick ;
Pouessel, Damien ;
Poulet, Claire ;
Fontaine-Delaruelle, Clara ;
Hiret, Sandrine ;
Dixmier, Adrien ;
Renault, Patrick-Aldo ;
Becht, Catherine ;
Raffy, Olivier ;
Dayen, Charles ;
Mazieres, Julien ;
Pichon, Eric ;
Langlais, Alexandra ;
Morin, Franck ;
Moro-Sibilot, Denis ;
Besse, Benjamin .
EUROPEAN JOURNAL OF CANCER, 2020, 131 :27-36
[5]   Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial [J].
Garon, Edward B. ;
Ciuleanu, Tudor-Eliade ;
Arrieta, Oscar ;
Prabhash, Kumar ;
Syrigos, Konstantinos N. ;
Goksel, Tuncay ;
Park, Keunchil ;
Gorbunova, Vera ;
Dario Kowalyszyn, Ruben ;
Pikiel, Joanna ;
Czyzewicz, Grzegorz ;
Orlov, Sergey V. ;
Lewanski, Conrad R. ;
Thomas, Michael ;
Bidoli, Paolo ;
Dakhil, Shaker ;
Gans, Steven ;
Kim, Joo-Hang ;
Grigorescu, Alexandru ;
Karaseva, Nina ;
Reck, Martin ;
Cappuzzo, Federico ;
Alexandris, Ekaterine ;
Sashegyi, Andreas ;
Yurasov, Sergey ;
Perol, Maurice .
LANCET, 2014, 384 (9944) :665-673
[6]   When is crossover desirable in cancer drug trials and when is it problematic? [J].
Haslam, A. ;
Prasad, V. .
ANNALS OF ONCOLOGY, 2018, 29 (05) :1079-1081
[7]   Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials [J].
Haslam, Alyson ;
Herrera-Perez, Diana ;
Gill, Jennifer ;
Prasad, Vinay .
JAMA NETWORK OPEN, 2020, 3 (03)
[8]  
Johnson M., 2022, LBA10 SOTORASIB VERS
[9]   ON SAMPLE SIZE CALCULATION FOR COMPARING SURVIVAL CURVES UNDER GENERAL HYPOTHESIS TESTING [J].
Jung, Sin-Ho ;
Chow, Shein-Chung .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (03) :485-495
[10]   IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves [J].
Liu, Na ;
Zhou, Yanhong ;
Lee, J. Jack .
BMC MEDICAL RESEARCH METHODOLOGY, 2021, 21 (01)